Welcome to our dedicated page for Artiva Biotherapeutics SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artiva Biotherapeutics filings document its clinical-stage biotechnology business, Nasdaq-listed common stock and material-event reporting. Recent Form 8-K disclosures cover quarterly and annual financial results, Regulation FD updates on AlloNK® (AB-101) clinical data, and exhibits such as press releases and corporate presentations.
The filing record also describes governance and compensation matters, including board and officer appointments, employment arrangements, non-employee director compensation, inducement awards and an option-for-RSU exchange under the 2024 Equity Incentive Plan. Artiva’s disclosures identify AlloNK as an off-the-shelf NK cell therapy candidate used with anti-CD20 monoclonal antibodies in autoimmune-disease trials, alongside standard public-company capital-structure and securities information.
Artiva Biotherapeutics, Inc. has filed a shelf registration statement permitting the offer and sale, from time to time, of up to $400,000,000 of common stock, preferred stock, debt securities and warrants. This structure allows the company to issue securities in multiple tranches using prospectus supplements.
The filing also includes an at-the-market program under an amended and restated sales agreement with Leerink Partners LLC, through which Artiva may sell up to $100,000,000 of common stock on the Nasdaq Global Market, where its shares trade under the symbol ARTV and last closed at $11.59 on August 5, 2026. Net proceeds are intended for working capital and general corporate purposes, including research and development, administrative expenses and capital expenditures.
Artiva Biotherapeutics, Inc. develops off-the-shelf allogeneic NK cell therapies for autoimmune diseases, led by AlloNK. For the quarter ended June 30, 2026, it reported a net loss of $25.0 million ($0.63 per share) and a six‑month net loss of $48.5 million.
Operating expenses increased as R&D reached $21.9 million in the quarter, driven largely by AlloNK. A May 2026 public offering of common stock and pre‑funded warrants generated $300.0 million in gross proceeds and $282.7 million net, lifting cash, cash equivalents and investments to $349.4 million and stockholders’ equity to $347.5 million.
Artiva reported encouraging AlloNK data in refractory rheumatoid arthritis, Sjögren’s disease and systemic sclerosis, with meaningful clinical responses and deep B‑cell depletion. The FDA granted Fast Track and RMAT designations for AlloNK in refractory RA and aligned on a single Phase 3 randomized trial of approximately 150 patients using ACR50 at six months as the primary endpoint. Management states existing capital should fund planned operations for at least one year, with additional financing required to complete development and potential commercialization.
Artiva Biotherapeutics, Inc. reported that on August 6, 2026 it issued a press release announcing its financial results for the quarter ended June 30, 2026. The press release is provided as Exhibit 99.1 and describes the company’s performance for that period.
The company explains that the information in this financial results press release, including Exhibit 99.1, is being furnished under the Exchange Act and is not deemed “filed” for purposes of Section 18 or automatically incorporated into other Securities Act or Exchange Act documents unless expressly stated. Artiva’s common stock trades on the Nasdaq Global Market under the symbol ARTV, and it is identified as an emerging growth company.
Artiva Biotherapeutics, Inc. will hold a virtual 2026 annual meeting on September 8, 2026, for stockholders of record as of July 20, 2026. Stockholders will vote to elect two Class II directors to serve until 2029, ratify KPMG LLP as independent auditor for 2026, and approve an amendment to the 2024 Equity Incentive Plan.
The amended plan would increase the share reserve by 5,097,095 shares to 13,328,057 shares and raise the incentive stock option limit to 39,984,171 shares. It also changes the annual “evergreen” formula so that, beginning in 2027, pre-funded warrants—currently exercisable into 2,170,138 shares—are included alongside outstanding common stock when calculating automatic share pool increases. Artiva reports 48,885,777 common shares outstanding as of the record date and recent equity plan burn rates of 11.8% for 2025 and 14.2% for 2024; KPMG billed audit fees of $750,355 in 2025 and $1,404,135 in 2024.
RA Capital Management-affiliated investment vehicles reported open-market purchases of 45,768 shares of Artiva Biotherapeutics common stock. On July 29, 2026 they bought 20,824 shares at a weighted average price of $9.99, and on July 31 they bought 24,944 shares at $9.93.
The shares are held indirectly through RA Capital-managed funds and a separately managed account, and the adviser and related parties disclaim beneficial ownership beyond their pecuniary interests. A partner of the adviser serves on Artiva’s board, providing board representation for these investors.
RA Capital Management, L.P. and affiliated funds reported purchasing 41,319 shares of Artiva Biotherapeutics, Inc. common stock on July 24, 2026 at a weighted average price of $9.99 per share, with trades between $9.96 and $10.00, held indirectly by RA Capital Healthcare Fund LP. The Adviser, its general partner, and Dr. Peter Kolchinsky and Mr. Rajeev Shah act as investment manager and managing members and disclaim beneficial ownership except to the extent of their pecuniary interest; additional Artiva shares are held through RA Capital Nexus funds and a separately managed account under similar terms.
RA Capital Management, L.P., together with Peter Kolchinsky, Rajeev Shah and affiliated funds, reports beneficial ownership of 18,415,956 shares of Artiva Biotherapeutics common stock, representing 37.9% of the class, with shared voting and dispositive power and no sole voting or dispositive power.
The position is held through RA Capital Healthcare Fund, L.P. with 17,242,483 shares, additional shares in Nexus funds and a separately managed account, pre-funded warrants for up to 2,170,138 shares, and 13,750 vested stock options held for RA Capital’s benefit. The pre-funded warrants include a 9.99% Beneficial Ownership Blocker, which currently prevents their exercise.
Between June 16 and July 23, 2026, the Fund bought multiple blocks of Artiva stock in open market transactions funded with working capital, at trade prices ranging from $8.62 to $10.00 per share. Percentage ownership uses a base of 24,716,672 shares outstanding as of April 30, 2026 plus 23,871,526 shares issued in a May 2026 offering and certain exercisable stock options. RA Capital and its managers may be deemed beneficial owners for Section 13(d) purposes but disclaim beneficial ownership outside these reporting obligations.
RA Capital Healthcare Fund LP, advised by RA Capital Management, reported open-market purchases of 264,586 shares of Artiva Biotherapeutics common stock on July 21–23, 2026, at weighted average prices of $9.55, $9.93, and $9.96 per share. The RA Capital entities and principals disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
Entities affiliated with RA Capital Management, L.P., significant stockholders and directors of Artiva Biotherapeutics, Inc., purchased 6,522 shares of common stock on July 13, 2026 at a weighted-average price of $8.94 per share (range $8.89–$8.95). Following this indirect purchase, the RA Capital funds reported holding 16,817,543 shares of Artiva common stock. The amendment corrects an earlier Form 4 share count, and notes the shares are held by RA Capital Healthcare Fund, L.P., with the Adviser and related parties disclaiming beneficial ownership except to the extent of their pecuniary interests.